MAPT and Alzheimer disease: While early breakthroughs—such as the identification of amyloid-β (Aβ) and tau—shaped the field over 25 years ago, progress since then has been incremental, underscoring the urgent need for novel insights into AD pathogenesis and therapeutic intervention [1].